
|Articles|November 15, 2016
SCRS Welcomes GlaxoSmithKline as a Global Impact Partner
The Society for Clinical Research Sites (SCRS) has announced GlaxoSmithKline (GSK) as its newest Global Impact Partner (GIP).
Advertisement
The Society for Clinical Research Sites (SCRS) has announced GlaxoSmithKline (GSK) as its newest Global Impact Partner (GIP). As a GIP, GSK will serve on the SCRS Global Impact Board and work closely with the organization’s Leadership Council on setting and working toward strategic initiatives.
Read the full release
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
FDA Makes Case for Overhauling Early Clinical Development to Reclaim US Leadership
2
Breaking the Efficacy Ceiling in IBD and Beyond
3
The Career They Didn't Train For: Rethinking Early-Career Burnout in Clinical Research
4
ACT Brief: Substance Versus Branding in Biotech Support, Site-Level Execution Gaps and Point-of-Care Data, and KCNT1-Targeted Pediatric Epilepsy Program
5



